Literature DB >> 32249842

PSMA PET-CT improves staging.

David Killock1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32249842     DOI： 10.1038/s41571-020-0364-4

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.

Authors:  Michael S Hofman; Nathan Lawrentschuk; Roslyn J Francis; Colin Tang; Ian Vela; Paul Thomas; Natalie Rutherford; Jarad M Martin; Mark Frydenberg; Ramdave Shakher; Lih-Ming Wong; Kim Taubman; Sze Ting Lee; Edward Hsiao; Paul Roach; Michelle Nottage; Ian Kirkwood; Dickon Hayne; Emma Link; Petra Marusic; Anetta Matera; Alan Herschtal; Amir Iravani; Rodney J Hicks; Scott Williams; Declan G Murphy
Journal:  Lancet       Date:  2020-03-22       Impact factor: 79.321
  1 in total
  2 in total

1.  Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression.

Authors:  Kathleen Ruchalski; Hyun J Kim; Michael Douek; Steven Raman; Maitraya Patel; Victor Sai; Antonio Gutierrez; Benjamin Levine; Cheryce Fischer; Martin Allen-Auerbach; Pawan Gupta; Heidi Coy; Bianca Villegas; Matthew Brown; Jonathan Goldin
Journal:  Cancer Imaging       Date:  2022-07-14       Impact factor: 5.605

2.  Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach.

Authors:  Hanane Lahnif; Tilmann Grus; Stefanie Pektor; Lukas Greifenstein; Mathias Schreckenberger; Frank Rösch
Journal:  Molecules       Date:  2021-10-20       Impact factor: 4.411
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.